SG11201505526TA - Peptide - Google Patents

Peptide

Info

Publication number
SG11201505526TA
SG11201505526TA SG11201505526TA SG11201505526TA SG11201505526TA SG 11201505526T A SG11201505526T A SG 11201505526TA SG 11201505526T A SG11201505526T A SG 11201505526TA SG 11201505526T A SG11201505526T A SG 11201505526TA SG 11201505526T A SG11201505526T A SG 11201505526TA
Authority
SG
Singapore
Prior art keywords
peptide
Prior art date
Application number
SG11201505526TA
Inventor
David Wraith
Heather Streeter
Original Assignee
Apitope Int Nv
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apitope Int Nv, Merck Serono Sa filed Critical Apitope Int Nv
Publication of SG11201505526TA publication Critical patent/SG11201505526TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
SG11201505526TA 2013-01-15 2014-01-13 Peptide SG11201505526TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1300684.6A GB201300684D0 (en) 2013-01-15 2013-01-15 Peptide
PCT/IB2014/058233 WO2014111840A2 (en) 2013-01-15 2014-01-13 Peptide

Publications (1)

Publication Number Publication Date
SG11201505526TA true SG11201505526TA (en) 2015-08-28

Family

ID=47757995

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201505526TA SG11201505526TA (en) 2013-01-15 2014-01-13 Peptide

Country Status (16)

Country Link
US (2) US9862751B2 (en)
EP (1) EP2945966B1 (en)
JP (1) JP6347065B2 (en)
KR (1) KR102169902B1 (en)
CN (1) CN105121463B (en)
AU (1) AU2014206592B2 (en)
BR (1) BR112015016780A2 (en)
CA (1) CA2897655C (en)
GB (1) GB201300684D0 (en)
HK (1) HK1211596A1 (en)
IL (1) IL239871B (en)
MX (1) MX369414B (en)
RU (1) RU2675479C2 (en)
SG (1) SG11201505526TA (en)
WO (1) WO2014111840A2 (en)
ZA (1) ZA201504987B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CN106986930B (en) * 2017-04-14 2021-06-11 广东省生物资源应用研究所 Protein for inducing experimental autoimmune encephalomyelitis of cynomolgus monkey and application
CN111225681A (en) * 2017-08-14 2020-06-02 艾匹托普技术(布里斯托尔)有限公司 Method of producing a composite material
GB201909774D0 (en) 2019-07-08 2019-08-21 Apitope Tech Bristol Limited Method

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7725894A (en) 1993-09-03 1995-03-22 Immulogic Pharmaceutical Corporation Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
US6251396B1 (en) 1994-11-18 2001-06-26 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
EP0922057A1 (en) * 1996-03-28 1999-06-16 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
SE9703287D0 (en) 1997-09-11 1997-09-11 Astra Ab Peptides
DE60043624D1 (en) 1999-03-12 2010-02-11 Univ R DNA vaccine for the treatment of autoimmune diseases
IL132611A0 (en) 1999-10-27 2001-03-19 Yeda Res & Dev Synthetic genes and polypeptides and pharmaceutical compositions comprising them
ATE475428T1 (en) 2000-03-29 2010-08-15 Univ Ohio State Res Found METHOD FOR BLOCKING THE DESTRUCTION OF TISSUE USING AUTOREACTIVE T CELLS
US20030191063A1 (en) 2000-08-21 2003-10-09 Wraith David Cameron Peptide selection method
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
IL161121A0 (en) 2001-10-03 2004-08-31 Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
CA2614171C (en) 2001-10-03 2012-04-24 President And Fellows Of Harvard College Copolymers for suppression of autoimmune diseases, and methods of use
IL146016A0 (en) 2001-10-17 2002-07-25 Yeda Res & Dev Synthetic peptides and dna sequences and compositions comprising them for treatment of multiple sclerosis
PT1456380E (en) 2001-11-02 2012-07-23 Giuliani Int Ltd Smad7 inhibitors for the treatment of cns diseases
CN100567987C (en) 2002-08-08 2009-12-09 贝勒医学院 T cell vaccine and preparation method thereof
EP2500438A3 (en) 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
WO2004104026A1 (en) 2003-05-21 2004-12-02 Biotech Tools S.A. Peptide complex
AU2011202900B2 (en) 2003-09-05 2012-08-02 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
CA2537759C (en) 2003-09-05 2015-03-24 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
AU2005308396B2 (en) 2004-11-29 2011-06-09 Yeda Research And Development Co. Ltd. Induction of neurogenesis and stem cell therapy in combination with Copolymer 1
US20080279878A1 (en) 2005-03-14 2008-11-13 B.G. Negev Technologies And Applications Ltd. Compositions of Hsp60 Peptides and Viral Antigens for Vaccination and Diagnosis
IL185932A (en) 2005-03-14 2014-02-27 Yeda Res & Dev Viral antigens, conjugates and compositions thereof for vaccination and diagnosis
AU2012201067A1 (en) 2005-03-14 2012-03-15 B.G. Negev Technologies And Applications Ltd. Compositions of HSP60 peptides and viral antigens for vaccination and diagnosis
US8202835B2 (en) 2005-06-17 2012-06-19 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
US20110027220A1 (en) 2005-09-28 2011-02-03 Cytos Biotechnology Ag Interleukin-1 Conjugates and Uses Thereof
US8128934B2 (en) 2005-11-14 2012-03-06 Ribomic, Inc. Method for treatment or prevention of disease associated with functional disorder of regulatory T cell
WO2007061805A2 (en) 2005-11-17 2007-05-31 The Cleveland Clinic Foundation Multipotent neural stem cells
US7803364B2 (en) 2005-11-17 2010-09-28 The Cleveland Clinic Foundation Multipotent neural stem cells
EP1991259B1 (en) 2006-02-15 2012-10-10 Ramot at Tel-Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
JP2009531295A (en) 2006-02-22 2009-09-03 ユニバーシティ オブ チューリッヒ Methods for treating autoimmune or demyelinating diseases
DK2016414T3 (en) 2006-05-05 2015-12-07 Opexa Therapeutics T-cell vaccine
AU2012202713B2 (en) 2006-05-31 2015-04-09 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
AU2012202776A1 (en) 2006-05-31 2012-05-31 Lpath, Inc. Novel Bioactive Lipid Derivatives, Immune-derived Moieties Reactive Thereto, and Methods of Making and Using Same
US8148084B2 (en) 2006-06-22 2012-04-03 Dana-Farber Cancer Institute, Inc. Diagnosis of autoimmune disease
US7832920B2 (en) 2006-10-25 2010-11-16 Revalesio Corporation Mixing device for creating an output mixture by mixing a first material and a second material
PT2087002E (en) 2006-10-27 2014-11-26 Lpath Inc Compositions and methods for binding sphingosine-1-phosphate
US8188218B2 (en) 2006-10-27 2012-05-29 University Of Kansas Bi-functional peptides for multiple sclerosis treatment and diagnosis
EP2164508B1 (en) 2007-06-04 2014-01-08 Rappaport Family Institute for Research in the Medical Sciences Agents for the treatment of inflammatory diseases and methods of using same
EP2050814A1 (en) 2007-10-17 2009-04-22 Txcell Compositions for treating multiple sclerosis
US20090227018A1 (en) 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
AU2008320657B2 (en) 2007-10-31 2013-09-05 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Composition
CA2715536C (en) 2008-02-14 2018-01-16 Life Sciences Research Partners Vzw Cd4+ t-cells with cytolytic properties
EP2355660A4 (en) 2008-10-13 2012-05-02 Biovista Inc Compositions and methods for treating multiple sclerosis
EP2364154A4 (en) 2008-10-22 2013-07-10 Revalesio Corp Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
AU2009315230A1 (en) 2008-11-12 2010-05-20 The Brigham And Women's Hospital, Inc. Diagnosis of multiple sclerosis
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
BRPI1013992A2 (en) 2009-04-27 2016-08-16 Revalesio Corp compositions and methods for treating insulin resistance and diabetes mellitus
US8703711B2 (en) 2009-06-09 2014-04-22 Val-Chum, Limited Partnership Ninjurin-1 modulation and uses thereof
US8293468B2 (en) 2009-06-10 2012-10-23 Centre Hospitalier De L'université De Montréal MCAM modulation and uses thereof
AU2010286351A1 (en) 2009-08-31 2012-03-15 Amplimmune, Inc. B7-H4 fusion proteins and methods of use thereof
CN102811739A (en) 2009-12-09 2012-12-05 田边三菱制药株式会社 T Cell Activation Inhibitor, Pharmaceutical Composition Containing Same, And Screening Method For T Cell Activation Inhibiting Substance
US20110189178A1 (en) 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
PL217128B1 (en) 2010-08-02 2014-06-30 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Synthetic genes encoding peptide fragments of natural myelin proteins intended to evoke the effect of food tolerance, DNA fragments containing these genes, process for the preparation of these peptides in a microbial (bacterial) system and their medical application
US10131875B2 (en) 2010-08-04 2018-11-20 Duke University Regulatory B cells and their uses
EP2600885A2 (en) 2010-08-04 2013-06-12 Ramot at Tel Aviv University, Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
WO2012021856A1 (en) 2010-08-12 2012-02-16 Revalesio Corporation Compositions and methods for treatment of taupathy
US20130171179A1 (en) 2010-09-03 2013-07-04 Oregon Health & Science University Recombinant t-cell receptor ligands with covalently bound peptides
US20130236473A1 (en) 2010-09-16 2013-09-12 Osaka University Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants
WO2012041867A2 (en) 2010-09-27 2012-04-05 China Agricultural University Combined antigen and dna vaccine for preventing and treating autoimmune diseases
WO2012045324A1 (en) 2010-10-07 2012-04-12 Mediagnost Gesellschaft Fur Forschung Und Herstellung Von Diagnostika Gmbh Method for detecting a parkinson's disease and test system
WO2012056407A1 (en) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
EP2667888A4 (en) 2011-01-28 2015-11-11 Univ Oregon Health & Science Recombinant t cell ligands and antibodies that bind b cells for the treatment of autoimmune diseases
US8685404B2 (en) * 2011-01-31 2014-04-01 Oregon Health & Science University Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction
KR101918745B1 (en) 2011-03-01 2018-11-15 파넥스트 Baclofen and acamprosate based therapy of neurogical disorders
JP5878447B2 (en) 2012-09-12 2016-03-08 富士フイルム株式会社 Base makeup cosmetics
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide

Also Published As

Publication number Publication date
JP6347065B2 (en) 2018-06-27
CN105121463B (en) 2020-11-27
US20180086802A1 (en) 2018-03-29
EP2945966A2 (en) 2015-11-25
MX369414B (en) 2019-11-07
JP2016505008A (en) 2016-02-18
KR20150105365A (en) 2015-09-16
ZA201504987B (en) 2017-11-29
IL239871B (en) 2018-12-31
CA2897655A1 (en) 2014-07-24
MX2015009085A (en) 2016-02-16
WO2014111840A3 (en) 2014-10-30
HK1211596A1 (en) 2016-05-27
AU2014206592B2 (en) 2018-01-04
RU2675479C2 (en) 2018-12-19
EP2945966B1 (en) 2019-07-03
RU2015134356A (en) 2017-02-22
US10377800B2 (en) 2019-08-13
BR112015016780A2 (en) 2017-08-15
IL239871A0 (en) 2015-08-31
CA2897655C (en) 2023-04-04
AU2014206592A1 (en) 2015-07-23
GB201300684D0 (en) 2013-02-27
CN105121463A (en) 2015-12-02
KR102169902B1 (en) 2020-10-26
US20150353616A1 (en) 2015-12-10
US9862751B2 (en) 2018-01-09
WO2014111840A2 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
HK1216757A1 (en) Peptide compound
GB201311475D0 (en) Polypeptides
EP2989885A4 (en) Combine
HRP20180452T1 (en) Peptides
PT3061771T (en) Novel four-ctl epitope-joined peptide
HK1211596A1 (en) Peptide
GB201308057D0 (en) Protein
GB201309421D0 (en) Polypeptides
HK1211595A1 (en) Peptide
HK1198769A1 (en) Novel peptide
GB201315130D0 (en) Peptides
PL2983690T3 (en) Neuropeptide y-derived peptides
GB201401955D0 (en) Protein
GB201316660D0 (en) Peptides
GB201300381D0 (en) Peptides
GB201305465D0 (en) Novel peptides
GB201322749D0 (en) Cyclic peptide
GB201302031D0 (en) Protein
GB201302030D0 (en) Protein